XTL Biopharmaceuticals (XTLB) Short Interest Ratio & Short Volume → Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad) Free XTLB Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock AnalysisCompetitorsEarningsHeadlinesShort InterestSocial MediaStock AnalysisCompetitorsEarningsHeadlinesShort InterestSocial Media XTL Biopharmaceuticals Short Interest DataCurrent Short Interest22,400 sharesPrevious Short Interest60,200 sharesChange Vs. Previous Month-62.79%Dollar Volume Sold Short$57,792.00Short Interest Ratio0.0 Days to CoverLast Record DateApril 30, 2024Outstanding Shares5,450,000 sharesPercentage of Shares Shorted0.41%Today's Trading Volume5,788 sharesAverage Trading Volume13,487 sharesToday's Volume Vs. Average43% Short Selling XTL Biopharmaceuticals ? Sign up to receive the latest short interest report for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartXTLB Short Interest Over TimeXTLB Days to Cover Over TimeXTLB Percentage of Float Shorted Over Time Ad Allegiance GoldDoes this make you sick?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit XTL Biopharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202422,400 shares $57,792.00 -62.8%N/A0 $2.58 4/15/202460,200 shares $161,336.00 -86.2%N/A0.1 $2.68 3/31/2024437,200 shares $1.23 million +21,760.0%N/A0.6 $2.81 3/15/20242,000 shares $1,760.00 +11.1%N/A0 $0.88 2/29/20241,800 shares $1,531.26 -37.9%N/A0.6 $0.85 2/15/20242,900 shares $2,608.26 -42.0%N/A0.9 $0.90 Get the Latest News and Ratings for XTLB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/31/20245,000 shares $4,378.50 -27.5%N/A1.4 $0.88 1/15/20246,900 shares $6,009.90 +1.5%N/A1.9 $0.87 12/31/20236,800 shares $6,868.68 -32.7%N/A1.7 $1.01 12/15/202310,100 shares $9,965.67 -15.8%N/A3.9 $0.99 11/30/202312,000 shares $12,360.00 +36.4%N/A5.7 $1.03 11/15/20238,800 shares $6,864.00 -24.8%N/A2.7 $0.78 10/31/202311,700 shares $10,148.58 +62.5%N/A3.2 $0.87 10/15/20237,200 shares $6,480.00 -22.6%N/A1.3 $0.90 9/30/20239,300 shares $8,347.68 -3.1%N/A1.7 $0.90 9/15/20239,600 shares $9,311.04 +29.7%N/A1.5 $0.97 8/31/20237,400 shares $7,770.00 +236.4%N/A0.5 $1.05 8/15/20232,200 shares $2,086.26 +29.4%N/A0.2 $0.95 7/31/20231,700 shares $1,385.84 -19.1%N/A0.1 $0.82 7/15/20232,100 shares $2,142.00 -16.0%N/A0.1 $1.02 6/30/20232,500 shares $2,376.75 -28.6%N/A0.2 $0.95 6/15/20233,500 shares $4,620.00 -25.5%N/A0.2 $1.32 5/31/20234,700 shares $5,734.00 +27.0%N/A0.6 $1.22 5/15/20233,700 shares $4,477.00 +23.3%N/A0.5 $1.21 4/30/20233,000 shares $3,360.00 -55.2%N/A0.5 $1.12 4/15/20236,700 shares $8,241.00 -23.0%N/A1.7 $1.23 3/31/20238,700 shares $11,049.00 +117.5%N/A4.1 $1.27 3/15/20234,000 shares $4,920.00 +2.6%N/A1.6 $1.23 2/28/20233,900 shares $5,459.61 -7.1%N/A1.3 $1.40 2/15/20234,200 shares $5,586.00 -16.0%N/A1.5 $1.33 1/31/20235,000 shares $5,850.00 -12.3%N/A1.4 $1.17 1/15/20235,700 shares $7,866.00 +2,750.0%N/A1.7 $1.38 12/30/2022200 shares $242.00 -95.7%N/A0.1 $1.21 12/15/20224,700 shares $5,687.00 -6.0%N/A1 $1.21 11/30/20225,000 shares $6,650.00 +6.4%N/A1.2 $1.33 11/15/20224,700 shares $6,674.00 +261.5%N/A1 $1.42 10/31/20221,300 shares $1,677.00 -40.9%N/A0.3 $1.29 10/15/20222,200 shares $2,651.00 +83.3%N/A0.3 $1.21 9/30/20221,200 shares $1,332.00 -77.4%N/A0.2 $1.11 9/15/20225,300 shares $7,155.00 -22.1%N/A0.9 $1.35**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! (Ad)Learn more about why Zack’s has increased its price target on this company to a whopping $23.25!Click for Zack's full report 8/31/20226,800 shares $10,064.00 +4.6%N/A1.2 $1.48 8/15/20226,500 shares $11,115.00 +8.3%N/A1.2 $1.71 7/31/20226,000 shares $9,780.00 -25.9%N/A1.1 $1.63 7/15/20228,100 shares $12,231.00 +42.1%N/A2.9 $1.51 6/30/20225,700 shares $8,664.00 +11.8%N/A1.7 $1.52 6/15/20225,100 shares $7,854.00 -13.6%N/A1.5 $1.54 5/31/20225,900 shares $10,714.99 -37.2%N/A0.9 $1.82 5/15/20229,400 shares $15,886.00 +20.5%N/A1.5 $1.69 4/30/20227,800 shares $17,160.00 +9.9%N/A1.4 $2.20 4/15/20227,100 shares $16,685.00 +16.4%N/A1.2 $2.35 3/31/20226,100 shares $14,457.00 +96.8%N/A0.9 $2.37 3/15/20223,100 shares $6,616.95 +121.4%N/A0.3 $2.13 2/28/20221,400 shares $3,332.00 -17.7%N/A0.1 $2.38 2/15/20221,700 shares $4,114.00 No ChangeN/A0.1 $2.42 1/31/20221,700 shares $4,284.00 -56.4%N/A0.1 $2.52 1/15/20223,900 shares $11,349.00 -17.0%N/A0.1 $2.91 12/31/20214,700 shares $13,019.00 +147.4%N/A0.2 $2.77 12/15/20211,900 shares $5,567.00 -64.2%N/A0.1 $2.93 11/30/20215,300 shares $16,960.00 +960.0%N/A0.2 $3.20 11/15/2021500 shares $1,790.00 -58.3%N/A0 $3.58 10/29/20211,200 shares $4,584.00 -60.0%N/A0 $3.82 10/15/20213,000 shares $11,790.00 -85.2%N/A0 $3.93 9/30/202120,200 shares $88,476.00 +1.0%N/A0.1 $4.38 9/15/202120,000 shares $82,800.00 -68.7%N/A0.1 $4.14 8/31/202163,900 shares $316,305.00 +75.6%N/A0.4 $4.95 8/13/202136,400 shares $129,220.00 -15.7%N/A0.3 $3.55 7/30/202143,200 shares $151,200.00 +37.6%N/A0.5 $3.50 7/15/202131,400 shares $108,958.00 -35.3%N/A0.4 $3.47 6/30/202148,500 shares $193,515.00 +40.2%N/A3.4 $3.99 6/15/202134,600 shares $119,370.00 -2.8%N/A2.1 $3.45 5/28/202135,600 shares $125,682.24 +14.8%N/A1.5 $3.53 5/14/202131,000 shares $103,230.00 -19.7%N/A0.1 $3.33 4/30/202138,600 shares $137,416.00 -5.6%N/A0.1 $3.56 4/15/202140,900 shares $132,516.00 -1.2%N/A0.2 $3.24 3/31/202141,400 shares $136,206.00 -19.8%N/A0.2 $3.29 3/15/202151,600 shares $174,924.00 +719.1%N/A0.2 $3.39 2/26/20216,300 shares $19,152.00 -77.7%N/A0 $3.04 2/12/202128,200 shares $106,596.00 +464.0%N/A1 $3.78 1/29/20215,000 shares $16,100.00 -76.5%N/A0.2 $3.22 1/15/202121,300 shares $84,135.00 +88.5%N/A0.8 $3.95 12/31/202011,300 shares $35,764.50 -76.6%N/A0.4 $3.17 12/15/202048,200 shares $126,766.00 +518.0%N/A2.5 $2.63 11/30/20207,800 shares $19,573.32 -34.5%N/A0.5 $2.51 10/30/20206,900 shares $15,318.00 -46.1%N/A0.4 $2.22 10/15/202012,800 shares $27,904.00 -14.1%N/A0.7 $2.18 9/30/202014,900 shares $28,308.51 +156.9%N/A0.9 $1.90 9/15/20205,800 shares $12,586.00 +65.7%N/A0.3 $2.17 8/31/20203,500 shares $5,950.00 +483.3%N/A0.1 $1.70 8/14/2020600 shares $1,032.00 -45.5%N/A0 $1.72 7/31/20201,100 shares $1,732.50 -93.3%N/A0.1 $1.58**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! (Ad)Learn more about why Zack’s has increased its price target on this company to a whopping $23.25!Click for Zack's full report 7/15/202016,400 shares $25,060.84 +198.2%N/A0.9 $1.53 6/30/20205,500 shares $8,525.00 -16.7%N/A0.3 $1.55 6/15/20206,600 shares $9,075.00 -7.0%N/A0.4 $1.38 5/29/20207,100 shares $9,744.75 -47.0%N/A2.1 $1.37 5/15/202013,400 shares $18,626.00 -19.3%N/A2.7 $1.39 4/30/202016,600 shares $20,160.70 -3.5%N/A2.8 $1.21 4/15/202017,200 shares $19,780.00 -1.7%N/A2.4 $1.15 3/31/202017,500 shares $20,562.50 +10.1%N/A2 $1.18 3/13/202015,900 shares $16,536.00 +1.9%N/A1.7 $1.04 2/28/202015,600 shares $15,600.00 -7.7%N/A1.4 $1.00 2/14/202016,900 shares $18,083.00 -17.6%N/A1.8 $1.07 1/31/202020,500 shares $28,700.00 -3.3%N/A2.6 $1.40 1/15/202021,200 shares $30,740.00 +40.4%N/A3.5 $1.45 12/31/201915,100 shares $19,781.00 No ChangeN/A2.7 $1.31 XTLB Short Interest - Frequently Asked Questions What is XTL Biopharmaceuticals' current short interest? Short interest is the volume of XTL Biopharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 22,400 shares of XTLB short. Learn More on XTL Biopharmaceuticals' current short interest. Is XTL Biopharmaceuticals' short interest increasing or decreasing? XTL Biopharmaceuticals saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 22,400 shares, a drop of 62.8% from the previous total of 60,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does XTL Biopharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to XTL Biopharmaceuticals: FSD Pharma Inc. (1.00%), Pieris Pharmaceuticals, Inc. (1.12%), Edesa Biotech, Inc. (0.69%), RedHill Biopharma Ltd. (2.38%), Purple Biotech Ltd (1.18%), Kiora Pharmaceuticals, Inc. (0.56%), Tonix Pharmaceuticals Holding Corp. (1.89%), Eterna Therapeutics Inc. (1.15%), NeuroSense Therapeutics Ltd. (0.16%), Imunon, Inc. (3.95%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short XTL Biopharmaceuticals stock? Short selling XTLB is an investing strategy that aims to generate trading profit from XTL Biopharmaceuticals as its price is falling. XTLB shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against XTL Biopharmaceuticals? A short squeeze for XTL Biopharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of XTLB, which in turn drives the price of the stock up even further. How often is XTL Biopharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including XTLB, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: FSD Pharma Short Squeeze Pieris Pharmaceuticals Short Squeeze Edesa Biotech Short Squeeze RedHill Biopharma Short Squeeze Purple Biotech Short Squeeze Kiora Pharmaceuticals Short Squeeze Tonix Pharmaceuticals Short Squeeze Eterna Therapeutics Short Squeeze NeuroSense Therapeutics Short Squeeze Imunon Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:XTLB) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsThis Could be Your “Big Money” AI MomentInvestorPlaceDigitizing the $11T commodities sector with one tiny stockResource Stock DigestObama’s Forever Term [exposed]Porter & CompanyNew Options need New Trading StrategiesNetpicks